AFFILIATIONS
1 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
2 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
3 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
4 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
5 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
6 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
7 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
8 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
9 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
10 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
11 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Milano-Bicocca, Monza, Italy
12 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
13 San Bortolo Hospital, Vicenza, Italy
14 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
15 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
16 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
17 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
18 Città della Speranza, Padua, Italy, University of Padua, Padua, Italy
19 University of Milano-Bicocca, Monza, Italy
20 Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, United States, European Institute of Oncology IRCCS, Milan, Italy, University of Torino, Torino, Italy
21 University of Milano-Bicocca, Monza, Italy
22 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
23 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
ABSTRACT
Introduction
Anaplastic lymphoma kinase (ALK) rearrangements drive several rare lymphoid malignancies, including ALK-positive anaplastic large-cell lymphoma (ALK+ ALCL), ALK-positive large B-cell lymphoma (ALK+ LBCL), and ALK-positive histiocytosis. Although many patients respond to chemotherapy and first-generation ALK tyrosine kinase inhibitors (TKIs), outcomes after ALK TKI failure remain poor. Lorlatinib, a third-generation ALK/ROS1 TKI with activity against multiple ALK resistance mutations, may overcome resistance to earlier-generation TKIs. To our knowledge, this is the first prospective phase II study evaluating lorlatinib in patients with relapsed/refractory (R/R) ALK-positive lymphoid malignancies after prior ALK TKI failure.
Methods
This phase II, open-label study (NCT03505554) enrolled patients with histologically confirmed R/R ALK-positive lymphoma or ALK-positive histiocytosis previously treated with ≥1 ALK inhibitor. Lorlatinib was administered at 100 mg orally once daily until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR), assessed by 18F-FDG PET according to Lugano criteria (complete metabolic response (CMR) and partial metabolic response (PMR) were considered as responses). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and minimal residual disease (MRD) assessed by RT-PCR for ALK-rearranged transcripts.
Results
Between January 2019 and December 2025, 9 patients were enrolled (median age, 21 years (range, 18-57)): ALK+ LBCL (n=4), ALK+ ALCL (n=4), and ALK-positive histiocytosis (n=1). At a median follow-up of 28 months (range, 1-78), ORR was 100% (95% CI, 66-100). Four patients (44%) achieved CMR after 1 month, all with concomitant RT-PCR negativity. Five patients (56%) achieved PMR; three converted to CMR by month 3, whereas two progressed and died. Five patients subsequently underwent allogeneic hematopoietic stem cell transplantation (allo-SCT), including two in CMR. Two patients in CMR at 1 month decided to postpone allo-SCT and remain in CMR at 78 and 28 months, respectively. Median PFS and OS were not reached; estimated 18-month PFS and OS rates were 75% and 88%, respectively. Early CMR at 1 month together with MRD negativity was associated with improved survival outcomes (P=0.04). Lorlatinib was well tolerated, with predominantly grade 1-2 adverse events (grade 3 hypercholesterolemia occurred in one patient).
Conclusions
Lorlatinib demonstrated high and durable antitumor activity with a favorable safety profile in patients with R/R ALK-positive lymphoid malignancies after prior ALK TKI therapy. Early metabolic response by 18F-FDG PET combined with MRD assessment by RT-PCR may identify patients most likely to achieve sustained remission and help guide decisions regarding treatment consolidation. Further and larger studies are warranted.